Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · NSE
· Updated 16 June 2026
₹2,273.1
↑ 13.04% (1Y)
🎯 Key Takeaways
- Revenue grew 1.7% QoQ to ₹5,768 in Q3FY25.
Market Cap
₹1.04 L Cr
P/E Ratio
36.2
Div Yield
0.00%
Promoter
0.0%
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 |
| Operating Profit | 615 | 879 | 958 | 1,067 | 1,026 | 1,309 | 1,383 | 1,410 |
| OPM % | 13.0% | 17.8% | 18.2% | 20.0% | 20.1% | 22.2% | 23.6% | 23.5% |
| Net Profit | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 |
| EPS | ₹5.19 | ₹9.94 | ₹10.76 | ₹13.47 | ₹7.89 | ₹17.58 | ₹18.70 | ₹18.75 |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
📋 Recent Filings
-
Announcement 8 June 2026Lupin announced a strategic partnership with Spanish pharmaceutical company ERN to launch Luforbec® (beclometasone/formoterol) pMDI for asthma and COP...
-
Announcement 4 June 2026Lupin announced U.S. FDA approval of its biosimilar ranibizumab (Ranluspec™) as an interchangeable product for Lucentis, expanding access to wet age-r...
-
🔴 Corporate Action 3 June 2026Lupin announced on June 3, 2026, that its Operations and Finance Committee allotted 16,673 fully paid-up equity shares of ₹2 each under its ESOP, incr...
-
Announcement 3 June 2026Lupin and Natco announced U.S. FDA approval for their generic version of Eribulin Mesylate Injection, a treatment for metastatic breast cancer and lip...
-
Announcement 29 May 2026Lupin Limited announced that its pending acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. has been delayed and is n...
-
Announcement 25 May 2026Lupin Limited announced its participation in three upcoming investor conferences in early June 2026, including BofA Securities, Morgan Stanley, and Ci...
-
Announcement 22 May 2026Lupin announced that China's National Medical Products Administration approved its Abbreviated New Drug Application for Oseltamivir Phosphate Oral Sus...
-
Announcement 18 May 2026Lupin announced it has received tentative U.S. FDA approval for its generic Revefenacin Inhalation Solution, a treatment for COPD that is bioequivalen...
-
🔴 Financial Results 14 May 2026Lupin Limited reported record FY26 revenue of **₹27,958 crores**, up 23% YoY, driven by 40% growth in U.S. sales and strong performance across India a...
-
Announcement 8 May 2026Lupin Limited announced that the audio recording of its Q4 FY26 earnings call, held on May 8, 2026 at 16:00 IST, is now available on its website for i...
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.